Horizon Pharma PLC HZNP shares are trading higher by 60 cents (5.6 percnet) at $13.30 in Monday's session.
The catalyst for the rally is a Q2 EPS beat of 31 cents along with a sales beat of $52.50 million. The company raised its FY 2017 guidance for net sales and adjusted EBITDA.
Immediately following the report, Horizon hit $15.50 in pre-market trading, but has come nowhere near that level in the regular session. After a higher open, it rallied only another 9 cents to $14.05 and reversed course.
So far, the ensuing decline has found support ahead of the top of Friday's range ($12.70) as $13.03 stands as the lows for the session as of 11:00 a.m. EST.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.